New Year Special 70% Discount Offer - Ends in 0d 00h 00m 00s - Coupon code: save70

Note! The SEND Exam is no longer valid. To find out more, please contact us through our Live Chat or email us.

MRCPUK SEND Exam With Confidence Using Practice Dumps

Exam Code:
SEND
Exam Name:
SEND - Endocrinology and Diabetes (Specialty Certificate Examination)
Vendor:
Questions:
200
Last Updated:
Dec 22, 2024
Exam Status:
Stable
MRCPUK SEND

SEND: MRCPUK Other Certification Exam 2024 Study Guide Pdf and Test Engine

Are you worried about passing the MRCPUK SEND (SEND - Endocrinology and Diabetes (Specialty Certificate Examination)) exam? Download the most recent MRCPUK SEND braindumps with answers that are 100% real. After downloading the MRCPUK SEND exam dumps training , you can receive 99 days of free updates, making this website one of the best options to save additional money. In order to help you prepare for the MRCPUK SEND exam questions and verified answers by IT certified experts, CertsTopics has put together a complete collection of dumps questions and answers. To help you prepare and pass the MRCPUK SEND exam on your first attempt, we have compiled actual exam questions and their answers. 

Our (SEND - Endocrinology and Diabetes (Specialty Certificate Examination)) Study Materials are designed to meet the needs of thousands of candidates globally. A free sample of the CompTIA SEND test is available at CertsTopics. Before purchasing it, you can also see the MRCPUK SEND practice exam demo.

Related MRCPUK Exams

SEND - Endocrinology and Diabetes (Specialty Certificate Examination) Questions and Answers

Question 1

A 55-year-old woman presented with a 3-week history of nausea and vomiting. Her only medical complaints were frequent dyspepsia, for which she was taking indigestion tablets, and asthma for which she was taking a salbutamol inhaler as required.

On examination, there was no evidence of lymphadenopathy, her chest was clear on auscultation and abdominal examination was normal.

Investigations (before and after taking omeprazole for 3 weeks):

beforeafternormal

erythrocyte sedimentation rate (mm/1st h)44<30

serum creatinine (µmol/L)17011060–110

serum corrected calcium (mmol/L)2.852.402.20–2.60

serum phosphate (mmol/L)1.90.8–1.4

serum angiotensin-converting enzyme (U/L)8525–82

plasma parathyroid hormone (pmol/L)0.44.40.9–5.4

What is the most likely cause of the hypercalcaemia?

Options:

A.

milk–alkali syndrome

B.

multiple myeloma

C.

parathyroid hormone-related peptide-secreting malignancy

D.

primary hyperparathyroidism

E.

sarcoidosis

Buy Now
Question 2

A 66-year-old woman was admitted with carpopedal spasm. During the previous week she had had 2 days of diarrhoea following treatment with ciprofloxacin for a urinary tract infection. She had long-standing rheumatoid arthritis treated with prednisolone 5 mg daily, and was also taking alendronic acid, omeprazole and furosemide.

Investigations:

serum creatinine115 ?mol/L (60–110)

serum corrected calcium1.79 mmol/L (2.20–2.60)

serum alkaline phosphatase124 U/L (45–105)

serum magnesium0.26 mmol/L (0.75–1.05)

plasma parathyroid hormone2.7 pmol/L (0.9–5.4)

Which medicine is most likely to be responsible for her metabolic derangement?

Options:

A.

alendronic acid

B.

ciprofloxacin

C.

furosemide

D.

omeprazole

E.

prednisolone

Question 3

A 45-year-old man had type 2 diabetes mellitus of 2 years’ duration. He had no history of ischaemic heart disease or microvascular complications, and was euthyroid. There was no family history of ischaemic heart disease. He was a non-smoker and drank 4 to 8 units of alcohol per week. He was taking metformin only.

On examination, his blood pressure was 120/78 mmHg and his body mass index was 24 kg/m2 (18–25).

His calculated 10-year cardiovascular risk was 8.5%.

Investigations (fasting):

serum sodium142 mmol/L (137–144)

serum potassium3.8 mmol/L (3.5–4.9)

serum creatinine90 µmol/L (60–110)

haemoglobin A1c48 mmol/L (20–42)

urinary albumin:creatinine ratio1.5 mg/mmol (<2.5)

serum cholesterol5.1 mmol/L (<5.2)

serum HDL cholesterol1.50 mmol/L (>1.55)

fasting serum triglycerides1.22 mmol/L (0.45–1.69)

What does the NICE guidance (CG181, July 2014) on type 2 diabetes mellitus recommend as the most appropriate next step in management?

Options:

A.

atorvastatin

B.

micronised fenofibrate

C.

no change

D.

omega-3 marine triglycerides

E.

simvastatin